EUVIMEDEUVIMED entdecken
Crossref

mRNA-Based Vaccination Drives in Vivo Dendritic Cell Reprogramming and Selective Cytotoxic T Lymphocyte Modulation for Enhanced Antitumor Immunity

Chenshuang Zhang, William Stewart, Yilong Teng, Bin Hu, Xiaoyang Xu iD, Xue-Qing Zhang iD

ACS Nano · 11.11.2025 · 19 (44) · 38267-38283

DOI: 10.1021/acsnano.5c09365 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, online erschienen am 28.10.2025. Verfasst von Chenshuang Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Innovative Immunotherapy, Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmace…. Hauptthemen laut MEDLINE: Dendritic Cells, T-Lymphocytes, Cytotoxic, Cancer Vaccines, RNA, Messenger. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Natural Science Foundation of Shanghai Municipality, National Key Research and Development Program of China, National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic CellsT-Lymphocytes, CytotoxicCancer VaccinesRNA, MessengerAnimalsMiceMice, Inbred C57BLVaccinationNanoparticlesFemaleImmunotherapyCell Line, TumorMelanoma, Experimental

Stichwörter der Autor:innen

cytotoxic T lymphocytesdendritic cell reprogramminglipid nanoparticlemRNAtumor vaccine

Substanzen

Cancer VaccinesRNA, Messenger

Autor:innen und Institutionen

  • National Key Laboratory of Innovative Immunotherapy, Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.
  • Department of Chemical and Materials Engineering, New Jersey Institute of Technology, Newark, New Jersey 07102, United States.
  • Department of Biomedical Engineering, New Jersey Institute of Technology, Newark, New Jersey 07102, United States.
  • Suzhou Biomedical Industry Innovation Center, Suzhou 215000, China.

ORCID-Profile: Xiaoyang Xu, Xue-Qing Zhang

Förderung

  • Natural Science Foundation of Shanghai Municipality
  • National Key Research and Development Program of China
  • National Science Foundation
  • ?Open Competition to Select the Best Candidates? Key Technology Program for Nucleic Acid Drugs of NCTIB
  • Program of Shanghai Frontiers Science Center of Drug Target Identification and Delivery
  • Gustavus and Louise Pfeiffer Research Foundation Award

Zitieren

APA

Zhang, C., Stewart, W., Teng, Y., Hu, B., Xu, X., & Zhang, X. Q. (2025). mRNA-Based Vaccination Drives in Vivo Dendritic Cell Reprogramming and Selective Cytotoxic T Lymphocyte Modulation for Enhanced Antitumor Immunity. ACS Nano, 19(44), 38267-38283. https://doi.org/10.1021/acsnano.5c09365

Vancouver

Zhang C, Stewart W, Teng Y, Hu B, Xu X, Zhang XQ. mRNA-Based Vaccination Drives in Vivo Dendritic Cell Reprogramming and Selective Cytotoxic T Lymphocyte Modulation for Enhanced Antitumor Immunity. ACS Nano. 2025;19(44):38267-38283. doi:10.1021/acsnano.5c09365

BibTeX
@article{Zhang2025,
  author = {Zhang, Chenshuang and Stewart, William and Teng, Yilong and Hu, Bin and Xu, Xiaoyang and Zhang, Xue-Qing},
  title = {mRNA-Based Vaccination Drives in Vivo Dendritic Cell Reprogramming and Selective Cytotoxic T Lymphocyte Modulation for Enhanced Antitumor Immunity},
  journal = {ACS Nano},
  year = {2025},
  volume = {19},
  number = {44},
  pages = {38267--38283},
  doi = {10.1021/acsnano.5c09365}
}
Kostenlos starten →